FR16C0015I1 - - Google Patents

Info

Publication number
FR16C0015I1
FR16C0015I1 FR16C0015C FR16C0015I1 FR 16C0015 I1 FR16C0015 I1 FR 16C0015I1 FR 16C0015 C FR16C0015 C FR 16C0015C FR 16C0015 I1 FR16C0015 I1 FR 16C0015I1
Authority
FR
France
Prior art keywords
pref
iii
pertussis
toxoid
agg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/433,646 external-priority patent/US5877298A/en
Application filed filed Critical
Publication of FR16C0015I1 publication Critical patent/FR16C0015I1/fr
Application granted granted Critical
Publication of FR16C0015I2 publication Critical patent/FR16C0015I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR16C0015C 1995-05-04 2016-04-27 Vaccins anticoquelucheux acellulaires et procedes de preparation correspondants Active FR16C0015I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/433,646 US5877298A (en) 1995-05-04 1995-05-04 Acellular pertussis vaccines and methods of preparing thereof
US50174395A 1995-07-12 1995-07-12
PCT/CA1996/000279 WO1996034883A1 (en) 1995-05-04 1996-05-02 Acellular pertussis vaccines and methods of preparation thereof

Publications (2)

Publication Number Publication Date
FR16C0015I1 true FR16C0015I1 (zh) 2016-06-10
FR16C0015I2 FR16C0015I2 (fr) 2017-06-09

Family

ID=27029924

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C0015C Active FR16C0015I2 (fr) 1995-05-04 2016-04-27 Vaccins anticoquelucheux acellulaires et procedes de preparation correspondants

Country Status (18)

Country Link
US (1) US6399076B2 (zh)
EP (7) EP1405643A1 (zh)
CN (2) CN100387618C (zh)
AT (3) ATE496634T1 (zh)
AU (2) AU710538B2 (zh)
BR (2) BR9608114A (zh)
CA (3) CA2433502A1 (zh)
DE (3) DE69622555T2 (zh)
DK (3) DK0824358T3 (zh)
ES (2) ES2182971T3 (zh)
FR (1) FR16C0015I2 (zh)
HK (1) HK1016191A1 (zh)
LU (1) LU93036I2 (zh)
MX (1) MX9708481A (zh)
NL (1) NL300804I2 (zh)
NZ (2) NZ306391A (zh)
PT (3) PT826001E (zh)
WO (2) WO1996034623A1 (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646776B1 (fr) * 1989-05-12 1994-06-03 Pasteur Institut Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
ATE183194T1 (de) * 1994-04-28 1999-08-15 Takeda Chemical Industries Ltd Verfahren zur trennung von protektiven verbindungen aus bordetella pertussis
US6696065B1 (en) * 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
GB9611501D0 (en) * 1996-06-03 1996-08-07 Smithkline Beecham Biolog Vaccine compositions
JP3280675B2 (ja) * 1996-07-02 2002-05-13 コノート ラボラトリーズ リミテッド 多価ｄｔｐポリオワクチン
JP4530317B2 (ja) * 1998-10-21 2010-08-25 学校法人北里研究所 減毒化トキシンを含むワクチン製剤
CA2546343A1 (en) * 2003-11-20 2005-06-09 Sanofi Pasteur, Inc. Methods for purifying pertussis toxin and peptides useful therefor
JP5378685B2 (ja) * 2004-12-17 2013-12-25 デ スタート デール ネーダーランデン， フェルテヘンウォールディヒィト ドール デ ミニステール ファン フォルクスヘーゾンドハイド， フェルザイン アン スポルト グラム陰性菌におけるｌｐｓの脱アシル化
US8124397B2 (en) * 2005-08-08 2012-02-28 Oregon Health & Science University Inactivating pathogens with oxidizing agents for vaccine production
EP1867638A1 (de) * 2006-06-16 2007-12-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verfahren zur kovalenten Verknüpfung zweier Moleküle mittels Diels-Alder-Reaktion mit inversem Elektronenbedarf
PL2097102T3 (pl) 2006-09-07 2012-10-31 Glaxosmithkline Biologicals Sa Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio
CN100537767C (zh) * 2007-04-29 2009-09-09 中国药品生物制品检定所 百日咳疫苗保护性抗原的重组表达及其应用
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
US20100330158A1 (en) * 2009-03-31 2010-12-30 Innopharma, Llc Protein-assisted drug delivery system for the targeted administration of active agents
EP2430040A1 (en) 2009-05-11 2012-03-21 Novartis AG Antigen purification process for pertactin antigen
WO2013043608A1 (en) * 2011-09-20 2013-03-28 Bio-Rad Laboratories, Inc. Removal of virucidal agents from biomolecule preparations
US20140234360A1 (en) 2011-09-30 2014-08-21 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Influenza vaccine
CN102584958A (zh) * 2012-02-08 2012-07-18 北京天坛生物制品股份有限公司 百日咳杆菌69kd外膜蛋白的纯化方法
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
ES2597832T3 (es) 2013-03-08 2017-01-23 Janssen Vaccines & Prevention B.V. Vacuna acelular contra la tosferina
SG10201911134QA (en) 2015-06-05 2020-01-30 Grace W R & Co Adsorbent bioprocessing clarification agents and methods of making and using the same
CN105106947A (zh) * 2015-07-21 2015-12-02 华兰生物工程股份有限公司 过氧化氢脱毒的无细胞百日咳疫苗及其制备方法
EP3518968B1 (en) 2016-10-03 2022-01-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hiv-1 env fusion peptide immunogens and their use
WO2018081832A1 (en) 2016-10-31 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
US11235056B2 (en) 2017-03-24 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glycan-masked engineered outer domains of HIV-1 gp120 and their use
KR102426041B1 (ko) * 2017-08-01 2022-07-29 주식회사 녹십자 냉동 및 해동 과정을 포함하는 백일해균 유래 단백질 수득 방법
WO2019079337A1 (en) 2017-10-16 2019-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE
WO2020061564A1 (en) 2018-09-23 2020-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use
US20210340188A1 (en) 2018-10-22 2021-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Recombinant gp120 protein with v1-loop deletion
CN110358802B (zh) * 2019-08-16 2021-06-18 长春百克生物科技股份公司 一种去除百日咳组分菌毛蛋白2/3内毒素的方法
CN112094354B (zh) * 2020-11-05 2021-02-02 苏州世诺生物技术有限公司 副鸡禽杆菌基因工程亚单位疫苗、其制备方法及应用
WO2023015186A1 (en) 2021-08-03 2023-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
WO2023192835A1 (en) 2022-03-27 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Base-covered hiv-1 envelope ectodomains and their use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
GB8601279D0 (en) * 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
US4705686A (en) 1986-05-09 1987-11-10 American Cyanamid Process for the preparation of acellular Bordetalla pertussis vaccine
JP2918895B2 (ja) * 1987-09-04 1999-07-12 アムジエン・インコーポレーテツド 組換え型ｄｎａ由来ボルデテラ毒素サブユニット類似体
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8807860D0 (en) 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
US4967176A (en) * 1988-07-15 1990-10-30 Raychem Corporation Assemblies of PTC circuit protection devices
US5101014A (en) 1989-02-10 1992-03-31 United States Of America Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
WO1990012086A1 (en) * 1989-03-31 1990-10-18 Washington University Bordetella vaccines
US5276142A (en) 1989-12-11 1994-01-04 American Cyanamid Company Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
GB9007657D0 (en) * 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
ATE183194T1 (de) * 1994-04-28 1999-08-15 Takeda Chemical Industries Ltd Verfahren zur trennung von protektiven verbindungen aus bordetella pertussis
FR2728170A1 (fr) * 1994-12-15 1996-06-21 Pasteur Institut Vaccin de type acellulaire anti-bordetella
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof

Also Published As

Publication number Publication date
ATE228851T1 (de) 2002-12-15
LU93036I2 (fr) 2016-06-21
DE69625191D1 (de) 2003-01-16
EP1234579A1 (en) 2002-08-28
ES2182971T3 (es) 2003-03-16
EP0826001A1 (en) 1998-03-04
FR16C0015I2 (fr) 2017-06-09
CA2220063C (en) 2003-08-26
EP1405643A1 (en) 2004-04-07
AU5494096A (en) 1996-11-21
BR9608115A (pt) 2004-07-13
DK1393744T3 (da) 2011-05-30
CA2220063A1 (en) 1996-11-07
US6399076B2 (en) 2002-06-04
DE69638326D1 (de) 2011-03-10
MX9708481A (es) 1998-02-28
CN1198099A (zh) 1998-11-04
NZ306392A (en) 1999-04-29
EP1234580A1 (en) 2002-08-28
AU715417B2 (en) 2000-02-03
EP1233022B1 (en) 2015-12-09
EP1393744B1 (en) 2011-01-26
ES2180758T3 (es) 2003-02-16
CA2433502A1 (en) 1996-11-07
DE69622555D1 (de) 2002-08-29
NL300804I2 (zh) 2016-11-01
NZ306391A (en) 1999-03-29
EP0824358A1 (en) 1998-02-25
PT826001E (pt) 2002-12-31
CA2220048C (en) 2006-03-07
ATE496634T1 (de) 2011-02-15
PT824358E (pt) 2003-02-28
CN100387618C (zh) 2008-05-14
AU5494196A (en) 1996-11-21
WO1996034883A1 (en) 1996-11-07
DE69622555T2 (de) 2003-03-27
CN1193324A (zh) 1998-09-16
EP0824358B1 (en) 2002-12-04
ATE221081T1 (de) 2002-08-15
HK1016191A1 (en) 1999-10-29
EP1233022A1 (en) 2002-08-21
US20010009666A1 (en) 2001-07-26
DE69625191T2 (de) 2003-07-10
CA2220048A1 (en) 1996-11-07
EP1393744A1 (en) 2004-03-03
AU710538B2 (en) 1999-09-23
BR9608114A (pt) 2000-10-31
PT1393744E (pt) 2011-05-03
DK0824358T3 (da) 2003-01-27
WO1996034623A1 (en) 1996-11-07
DK0826001T3 (da) 2002-11-18
EP0826001B1 (en) 2002-07-24

Similar Documents

Publication Publication Date Title
NL300804I2 (zh)
AU4267093A (en) Vaccine compositions for mucosal delivery
RU99101850A (ru) Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно(акдс)-полиомиелитные вакцины
CA2271008A1 (en) Acellular pertussis vaccine with diphtheria- and tetanus-toxoids
LU91155I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutininine filamenteuse, de pertactine, d'agglutinogènes fimbriaux coquelucheux 2 et 3 et de virus poliomyélitique inactivé type 1, type 2 et type 3.
EP0761230A3 (en) Vaccine containing Bordetella pertussis outer membrane protein, and method of making such vaccine
WO1997045139A3 (en) Il-12 as an adjuvant for bordetella pertussis vaccines
AU5625796A (en) Protective epitopes of adenyl cyclase-haemolysin(AC-Hly), their application to the treatment or to the prevention of bordetella infections
WO1997046255A3 (en) Vaccine composition comprising outer membrane protein fragments of bordetella pertussis
Mauro et al. Further observations on a dipheheria-tetanus vaccine adult type.
MXPA99004278A (es) Vacuna de pertusis acelular con toxoides de difteria y tetanos